Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Invasive disease caused by type b (Hib) is a major health concern, particularly in children under 5 years of age and vulnerable populations. Use of Hib conjugate vaccines has significantly reduced the incidence of Hib disease. Among these, the polyribosylribitol phosphate-outer membrane protein complex (PRP-OMPC) conjugate has demonstrated uniquely robust immunogenicity in infants compared to PRP conjugated to tetanus toxoid. Vaxelis, using the PRP-OMPC conjugate, was well tolerated and immunogenic as shown through the clinical development program. Additional studies that are recently published address previously open questions regarding Vaxelis, including immunogenicity after the first infant dose, co-administration with meningococcal B vaccine, and interchangeability with other hexavalent vaccines. This brief review summarizes recently published Vaxelis data, with potential implications for ongoing control of invasive Hib disease in Europe.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/21645515.2025.2553949 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Infant protection from invasive type b disease using the PRP-OMPC conjugate vaccine: An update.
Hum Vaccin Immunother
December 2025
Merck & Co. Inc., Rahway, NJ, USA.
Invasive disease caused by type b (Hib) is a major health concern, particularly in children under 5 years of age and vulnerable populations. Use of Hib conjugate vaccines has significantly reduced the incidence of Hib disease. Among these, the polyribosylribitol phosphate-outer membrane protein complex (PRP-OMPC) conjugate has demonstrated uniquely robust immunogenicity in infants compared to PRP conjugated to tetanus toxoid.
View Article and Find Full Text PDFDTaP5-HBV-IPV-Hib pediatric hexavalent combination vaccine for use in children from 6 weeks through to 4 years of age.
Expert Rev Vaccines
November 2019
Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Hospital Clínico Universitario and Universidad de Santiago de Compostela (USC), Galicia, Spain.
: Combination vaccines reduce the number of injections received by children, hence improving timeliness and coverage, and general acceptability among caregivers and health-care providers. The most recent hexavalent vaccine, DTaP5-HBV-IPV-Hib, has been also approved by the FDA.: DTaP5-HBV-IPV-Hib has demonstrated good immunogenic and safety profiles, not inferior to other hexavalent vaccines already in use in the European market.
View Article and Find Full Text PDFImmunogenicity and safety of a Haemophilus influenzae B (Hib)-hepatitis B vaccine with a modified process hepatitis B component administered with concomitant pneumococcal conjugate vaccine to infants.
Vaccine
October 2011
Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA.
Background: A hepatitis B vaccine was manufactured with a modified process (mpHBV) that incorporated double the usual amount of phosphate. Following a study in young adults, the mpHBV was evaluated in infants in a combination hepatitis B and Haemophilus influenzae B vaccine (mpHBV-Hib).
Methods: The mpHBV-Hib was compared with the licensed bivalent HBV-Hib vaccine Comvax™ for immunogenicity and safety.
Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of age.
Vaccine
February 2011
Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.
The current recommended infant vaccination schedules require many injections at multiple sites, which increase stress for infants and parents and may create challenges to vaccination compliance. Therefore, combination vaccines, which reduce the number of injections at each medical visit, can be an essential method to improve compliance. The objective of this study was to assess the safety and immunogenicity of an investigational, liquid, hexavalent, pediatric vaccine at 2, 4, 6, and 12-14 months of age.
View Article and Find Full Text PDFHaemophilus influenzae type b carriage in Indigenous children and children attending childcare centers in the Northern Territory, Australia, spanning pre- and post-vaccine eras.
Vaccine
April 2011
Child Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia.
Unlabelled: This paper investigates Haemophilus influenzae type b (Hib) carriage in Indigenous children and children attending childcare centres in the Northern Territory of Australia, 1992-2005. More than 10 years after the introduction of the Hib conjugate vaccine, Hib carriage persists in Indigenous children (3.4%, 2003-2005) and children attending childcare centres (0.
View Article and Find Full Text PDF